Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

James B. Nachman, Harland N. Sather, Martha G. Sensel, Michael E. Trigg, Joel M. Cherlow, John N. Lukens, Lawrence Wolff, Fatih M. Uckun, Paul S. Gaynon

Research output: Contribution to journalArticlepeer-review

332 Scopus citations

Abstract

Background: Children with high-risk acute lymphoblastic leukemia (ALL) who have a slow response to initial chemotherapy (more than 25 percent blasts in the bone marrow on day 7) have a poor outcome despite intensive therapy. We conducted a randomized trial in which such patients were treated with either an augmented intensive regimen of post-induction chemotherapy or a standard regimen of intensive post-induction chemotherapy. Methods: Between January 1991 and June 1995, 311 children with newly diagnosed ALL who were either 1 to 9 years of age with white-cell counts of at least 50,000 per cubic millimeter or 10 years of age or older, had a slow response to initial therapy, and entered remission at the end of induction chemotherapy were randomly assigned to receive standard therapy (156 children) or augmented therapy (155). Those with lymphomatous features were excluded. Event-free survival and overall survival were assessed from the end of induction treatment. Results: The outcome at five years was significantly better in the augmented-therapy group than in the standard-therapy group (Kaplan-Meier estimate of event-free survival [±SD]: 75.0±3.8 vs. 55.0±4.5 percent, P<0.001; overall survival: 78.4±3.7 vs. 66.7±4.2 percent, P=0.02). The difference between treatments was most pronounced among patients one to nine years of age, all of whom had white-cell counts of at least 50,000 per cubic millimeter (P<0.001). Risk factors for an adverse event in the entire cohort included a white-cell count of 200,000 per cubic millimeter or, higher (P=0.004), race other than black or white (P<0.001), and the presence of a t(9;22) translocation (P=0.007). The toxic effects of augmented therapy were considerable but manageable. Conclusions: Augmented post-induction chemotherapy results in an excellent outcome for most patients with high- risk ALL and a slow response to initial therapy.

Original languageEnglish (US)
Pages (from-to)1663-1671
Number of pages9
JournalNew England Journal of Medicine
Volume338
Issue number23
DOIs
StatePublished - Jun 4 1998

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy'. Together they form a unique fingerprint.

Cite this